Literature DB >> 21270790

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

M A Perera1, E Gamazon, L H Cavallari, S R Patel, S Poindexter, R A Kittles, D Nicolae, N J Cox.   

Abstract

It is well recognized that the genetic variants VKORC1-1639, CYP2C9*2, and CYP2C9*3 contribute to warfarin dose response. This has led to warfarin dosing algorithms that include these polymorphisms and explains between 47% and 56% of variability in dose in Caucasians. However, these polymorphisms explain significantly less of the variance in dose among African Americans. In order to identify novel variations that affect warfarin dose in African Americans, we used a targeted resequencing strategy that examined evolutionarily conserved sequences and regions of putative transcriptional binding. Through ethnicity-specific warfarin dose model building in 330 African Americans, we identified two novel genetic associations with higher warfarin dose, namely, VKORC1-8191 (rs61162043, P = 0.0041) and 18786 in CYP2C9 (rs7089580, P = 0.035). These novel finds are independent of the previous associations with these genes. Our regression model, encompassing both genetic and clinical variables, explained 40% of the variability in warfarin dose in African-American subjects, significantly more than any model thus far.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270790      PMCID: PMC3625373          DOI: 10.1038/clpt.2010.322

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  40 in total

1.  TRANSFAC: an integrated system for gene expression regulation.

Authors:  E Wingender; X Chen; R Hehl; H Karas; I Liebich; V Matys; T Meinhardt; M Prüss; I Reuter; F Schacherer
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium.

Authors:  Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson
Journal:  Am J Hum Genet       Date:  2003-12-15       Impact factor: 11.025

3.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Authors:  Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton
Journal:  Pharmacogenomics       Date:  2008-05       Impact factor: 2.533

Review 4.  The pharmacodynamics of the oral anticoagulant drugs.

Authors:  R A O'Reilly
Journal:  Prog Hemost Thromb       Date:  1974

5.  The association of vitamin K status with warfarin sensitivity at the onset of treatment.

Authors:  M Cushman; S L Booth; C J Possidente; K W Davidson; J A Sadowski; E G Bovill
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

Review 6.  Systematic overview of warfarin and its drug and food interactions.

Authors:  Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells
Journal:  Arch Intern Med       Date:  2005-05-23

7.  VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Authors:  Nita A Limdi; T Mark Beasley; Michael R Crowley; Joyce A Goldstein; Mark J Rieder; David A Flockhart; Donna K Arnett; Ronald T Acton; Nianjun Liu
Journal:  Pharmacogenomics       Date:  2008-10       Impact factor: 2.533

8.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Authors:  Farhad Kamali; Tayyaba Irfan Khan; Barry P King; Richard Frearson; Patrick Kesteven; Peter Wood; Ann K Daly; Hilary Wynne
Journal:  Clin Pharmacol Ther       Date:  2004-03       Impact factor: 6.875

9.  Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.

Authors:  Danxin Wang; Huizi Chen; Kathryn M Momary; Larisa H Cavallari; Julie A Johnson; Wolfgang Sadée
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

10.  Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.

Authors:  H Schelleman; J Chen; Z Chen; J Christie; C W Newcomb; C M Brensinger; M Price; A S Whitehead; C Kealey; C F Thorn; F F Samaha; S E Kimmel
Journal:  Clin Pharmacol Ther       Date:  2008-07-02       Impact factor: 6.875

View more
  51 in total

1.  Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.

Authors:  Y Liu; H Jeong; H Takahashi; K Drozda; S R Patel; N L Shapiro; E A Nutescu; L H Cavallari
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

2.  CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.

Authors:  Danxin Wang; Xiaochun Sun; Yan Gong; Brian E Gawronski; Taimour Y Langaee; Mohamed Hossam A Shahin; Sherief I Khalifa; Julie A Johnson
Journal:  Drug Metab Dispos       Date:  2012-01-30       Impact factor: 3.922

Review 3.  Personalized medicine: is it a pharmacogenetic mirage?

Authors:  Rashmi R Shah; Devron R Shah
Journal:  Br J Clin Pharmacol       Date:  2012-10       Impact factor: 4.335

4.  Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.

Authors:  W Hernandez; E R Gamazon; K Aquino-Michaels; S Patel; T J O'Brien; A F Harralson; R A Kittles; A Barbour; M Tuck; S D McIntosh; J N Douglas; D Nicolae; L H Cavallari; M A Perera
Journal:  Pharmacogenomics J       Date:  2013-09-10       Impact factor: 3.550

5.  A pharmacogenetics service experience for pharmacy students, residents, and fellows.

Authors:  Katarzyna Drozda; Yana Labinov; Ruixuan Jiang; Margaret R Thomas; Shan S Wong; Shitalben Patel; Edith A Nutescu; Larisa H Cavallari
Journal:  Am J Pharm Educ       Date:  2013-10-14       Impact factor: 2.047

6.  Warfarin dose requirements in a patient with the CYP2C9*14 allele.

Authors:  Yee Ming Lee; Jessica Eggen; Vinay Soni; Katarzyna Drozda; Edith A Nutescu; Larisa H Cavallari
Journal:  Pharmacogenomics       Date:  2014-05       Impact factor: 2.533

Review 7.  The future of warfarin pharmacogenetics in under-represented minority groups.

Authors:  Larisa H Cavallari; Minoli A Perera
Journal:  Future Cardiol       Date:  2012-07

8.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

9.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

10.  Genome-wide approaches in pharmacogenomics: heritability estimation and pharmacoethnicity as primary challenges.

Authors:  Eric R Gamazon; Minoli Perera
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.